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Abstract
Background: People with schizophrenia have a higher premature mortality risk compared with the general
population mainly due to cardiovascular disease (CVD). Despite this, people with schizophrenia are less likely to
access physical health services or have their physical health investigated and monitored.
Aims: To examine the beliefs and actions of mental health professionals regarding the physical health of people
with schizophrenia.
Method: Two hundred and fifty-five healthcare professionals who support people with schizophrenia within
Greater Manchester Mental Health NHS Foundation Trust (GMMH), United Kingdom and Pennine Care NHS
Foundation Trust (PCFT), United Kingdom took part. Beliefs and actions were assessed using a self-administered
questionnaire, which was constructed around two primary domains (1) CVD risk factors; and (2) physical health
interventions. Descriptive statistics were reported and responses between different healthcare professional groups
were compared.
Results: The overwhelming majority of participants were aware of established CVD risk factors with 98% identifying
family history of CVD, 98% for smoking and 96% for high blood pressure. Most participants believed nearly all
healthcare professionals were responsible for monitoring the physical health of people with schizophrenia,
regardless of job speciality. There were 67% of participants who reported delivering an intervention to improve
sedentary behaviour for people with schizophrenia. However, awareness of government and NHS recommended
lifestyle interventions were low.
Conclusions: This study found good knowledge regarding many established CVD risk factors but little clarity
regarding who is responsible for monitoring the physical health of people with schizophrenia and how often brief
lifestyle interventions are being implemented.
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Introduction
People with schizophrenia have a reduced life expectancy
by one to two decades and a premature mortality risk two
to three times higher than the general population [1–3].
The most common cause of death in this group is cardio-
vascular disease (CVD) [4–6], with a more than double
risk of death from CVD compared with the general popu-
lation, according to a large-scale meta-analysis [7]. Phys-
ical health comorbidity is one cause of the poor health
outcomes seen in this group, who have been shown to
have high prevalence of obesity [8], type 2 diabetes [9],
dyslipidaemia and hypertension [10]. Antipsychotic medi-
cation, prescribed to manage symptoms, can cause adverse
side effects of metabolic syndrome [11] (defined as central
obesity, plus any two of raised triglycerides, reduced high-
density lipoprotein-cholesterol, raised blood pressure,
raised fasting plasma glucose [12]). However, as increased
risk of cardiometabolic diseases in people with schizo-
phrenia can arise even prior to antipsychotic treatment
[13], unhealthy lifestyle factors may also play a part, in-
cluding increased prevalence of smoking [14], sedentary
behaviour [15] and dysregulated sleep patterns [16, 17].
An added problem is that people with schizophrenia are
less likely than people in the general population to report
physical health problems [18–20], access health services
for physical health concerns [21] and have these issues in-
vestigated and monitored [22, 23]. Lack of clarity about
who is responsible for the physical health of mental health
service users may contribute to this problem [24]. While
primary care staff likely have the necessary skills and ex-
pertise to perform physical health assessments, knowledge
and confidence may be lacking in relation to supporting
people with schizophrenia [25]. A survey found 47.2% of
practice nurses administer antipsychotic injections, yet
only 9.4% monitor for side effects using a validated rating
scale [26]. This can lead to ‘diagnostic overshadowing’
whereby treating healthcare professionals could attribute
physical symptoms to an existing mental health diagnosis
and subsequently do not investigate [27].
The aim of this study is therefore to examine the be-
liefs and actions of healthcare professionals who support
people with schizophrenia, in relation to their patients’
physical health.
Method
Sample
We surveyed healthcare professionals who were cur-
rently working in a job role that involved contact with
one or more individuals with a diagnosis of schizophre-
nia or related psychosis, according to the ICD-10 classi-
fication system [28]. Participants were recruited from
Greater Manchester Mental Health NHS Foundation
Trust (GMMH), United Kingdom (UK) and Pennine
Care NHS Foundation Trust (PCFT), UK. Participants
with a clinical role in supporting people with schizophre-
nia were identified and contacted by National Institute for
Health Research (NIHR) Clinical Research Network
(CRN) clinical studies officers (CSOs). The study received
ethical approval from the North West Research Ethics
Committee (17/NW/0368). It was also adopted by the
NIHR CRN Portfolio (34859). There were 255 participants
included in this study, 119 were recruited from GMMH
and 136 were recruited from PCFT.
Questionnaire development
The self-administered questionnaire was constructed
around two primary domains [1] CVD risk factors; and
[2] physical health interventions (Supplementary mate-
rials). The first section of the questionnaire asked about
gender, job specialty, area of work, time worked in the
profession and NHS trust. The second section asked
participants to select on a checklist: “Which of the fol-
lowing do you think are risk factors for cardiovascular
disease? Please tick all that apply”. Risk factors were in-
cluded based on published literature [29, 30] and UK na-
tional clinical guidelines to improve health and social
care by the National Institute for Health and Care Excel-
lence (NICE) [31, 32]. Additional misleading variables,
i.e. hair dye and mobile phone use, were also included as
options to determine if any participants simply checked
all items. Participants were excluded from the analyses if
all misleading items were checked. For the purpose of
this study, we considered risk factors to be established
predictors of CVD if they were stated as such in NICE
publications [31, 32] or used in algorithms for CVD risk
prediction scores that could be applied to people with
schizophrenia [33, 34].
The third section asked participants questions relating
to physical health monitoring and interventions. First,
participants were asked to select on a checklist which
healthcare professionals they felt were responsible for
monitoring the physical health of people with schizo-
phrenia. Second, participants were asked a dichotomous
question: “Have you ever delivered any effective inter-
ventions to improve sedentary behaviour in people with
schizophrenia?” If participants answered “yes” they were
then asked an open-ended question with a section to
write comments: “If you answered yes, please specify the
intervention(s)”. Finally, participants were asked dichot-
omous questions on whether they had heard of govern-
ment recommended lifestyle interventions; Making
Every Contact Count (MECC), which is an NHS ap-
proach for healthcare professionals to support lifestyle
related behaviour change in any patient they come into
contact with [35]; and Very Brief Advice (VBA) on
smoking, which involves short and simple advice that
healthcare professionals can provide opportunistically,
with any patient they come into contact with who
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smokes [36]. An additional misleading (i.e. non-existent)
intervention ‘VBA on sedentary behaviour’ was also in-
cluded. If participants selected “yes” to having heard of any
of these interventions, they were then asked if they had ever
delivered the intervention to someone with schizophrenia.
Questionnaire distribution
A cross-sectional online survey was distributed to partici-
pants within community mental health teams and inpatient
settings using SelectSurvey.net (v4·146·001; ClassApps, Over-
land Park, KS, U.S.A.). Additionally, the survey was available
in paper format for participants to complete and post back
to the research team if they preferred. Preferred method of
survey delivery was ascertained by the recruiting CSOs. All
individual responses were checked for each completed sur-
vey by a researcher to ensure participants did not submit du-
plications via SelectSurvey.net and paper format. Participants
received an information sheet to read, via SelectSurvey.net or
as an attachment with the paper version. As no identifiable
information was requested from participants, anonymity was
preserved.
Statistical analyses
After recruitment was completed, the survey was closed
and data were downloaded from the SelectSurvey.net
website and imported into Microsoft Excel software.
Data were then analysed using STATA (version 13; Sta-
tacorp, TX, USA). Descriptive statistics were reported as
percentages. Depending on their job role, healthcare
professionals were grouped as follows: Non-qualified
clinical staff, nurses, senior/managerial clinical staff, al-
lied health professionals and medical practitioners. Spe-
cifically, the non-qualified clinical staff group comprised
healthcare assistants/support workers, assistant psychol-
ogists, occupational therapy assistants, recovery/service
user co-ordinators and student nurses. The nurses group
comprised of mental health nurses (hospital), commu-
nity psychiatric nurses, clozapine nurses and research
nurses. The allied health professionals group comprised
psychologists, cognitive behavioural therapy (CBT) ther-
apists, occupational therapists, social workers, pharma-
cists and dietitians. The medical practitioners group
comprised consultant psychiatrists, junior doctors and
specialty doctors. A comparison between grouped
healthcare professionals and all survey responses was
made using Chi-square test, or where the expected cell
count was below 5, a Fisher’s exact test. Differences be-
tween the groups were considered statistically significant
if the p-value was less than 0.05.
Results
Summary data
In total 255 participants completed the survey between
May 2018 and September 2018, of whom 69% were
female and 41.9% were nurses. Summary data for partici-
pant characteristics can be seen in Table 1.
Risk factors for CVD
Almost all participants identified family history of CVD
(98%), smoking (98%) and high blood pressure (96%) as risk
factors for CVD. About three-quarters of participants identi-
fied age and antipsychotic/antidepressant medication as a
risk factor. Diabetes was identified as a risk factor for CVD
by 72%, ethnicity by 55% and sleep problems by 45% of par-
ticipants. Table 2 shows the findings from the full list of risk
factors that were available for participants to select. Among
the risk factors presented, Chi-square analyses revealed sig-
nificant differences between healthcare professional groups
(non-qualified clinical staff, nurses, senior/managerial clinical
staff, allied health professionals and medical practitioners) in
whether they believed that ethnicity, diabetes and anti-
psychotic/antidepressant medication are risk factors for
CVD (Table 3). Compared with other groups, non-qualified
Table 1 Characteristics of healthcare professionals (N = 255)
Number Percent
NHS Trust
GMMH 119 46.7
PCFT 136 53.3
Gender
Male 73 28.7
Female 176 69.3
Time in profession
Less than 1 year 15 5.9
1–4 years, 11 months 60 23.7
5–9 years, 11 months 50 19.8
10–19 years, 11 months 72 28.5
More than 20 years 56 22.1
Job role
Non-qualified clinical staff 69 27.3
Nurses 106 41.9
Senior/managerial clinical staff 14 5.5
Allied health professionals 42 16.6
Medical practitioners 22 8.7
Workplace
Inpatient care 115 45.3
Community mental health team 68 26.8
Early intervention in psychosis 30 11.8
Rehabilitation 15 5.9
Substance misuse services 4 1.6
Crisis resolution 6 2.4
A day unit 4 1.6
Other community services 12 4.7
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clinical staff were significantly less likely to identify ethnicity
(31.9% vs range: 57.1–77.3%, χ2 = 21.24; p < 0.001), diabetes
(60.9% vs range: 70.8–90.9%, χ2 = 9.77; p= 0.04) and anti-
psychotic/antidepressant medication (60.9% vs range: 71.4–
90.9%; χ2 = 10.60; p= 0.03) as CVD risk factors (Table 3).
Physical health monitoring
Responsibility
Similar numbers of participants believed the responsibil-
ity to monitor the physical health of schizophrenia was
that of general practitioners (GPs) (93%), mental health
Table 2 Summary of risk factors identified by professional groups for CVD (N = 255)
Risk factors Non-qualified clinical
staff
N (%)
Nurses
N (%)
Senior/managerial clinical
staff
N (%)
Allied health
professionals
N (%)
Medical
practitioners
N (%)
Total
N (%)
abFamily history of CVD 68 (98.6) 103
(97.2)
13 (92.9) 42 (100) 22 (100) 250
(98.0)
abSmoking 66 (95.7) 104
(98.1)
14 (100) 41 (97.6) 22 (100) 249
(97.7)
abHigh blood pressure 64 (92.8) 103
(97.2)
14 (100) 40 (95.2) 22 (100) 245
(96.1)
abObesity 63 (91.3) 102
(96.2)
11 (78.6) 40 (95.2) 22 (100) 240
(94.1)
abHigh cholesterol 63 (91.3) 97
(91.5)
14 (100) 41 (97.6) 22 (100) 239
(93.7)
aLack of physical activity 64 (92.8) 96
(90.1)
14 (100) 39 (92.9) 21 (95.5) 236
(92.6)
bAlcohol consumption 60 (87.0) 93
(87.7)
11 (78.6) 32 (76.2) 18 (81.8) 216
(84.7)
cPoor diet 54 (78.3) 93
(87.7)
12 (85.7) 32 (76.2) 20 (90.9) 212
(83.1)
cSubstance abuse 58 (84.1) 87
(82.1)
11 (78.6) 33 (78.6) 16 (72.3) 206
(80.8)
abAge 49 (71.0) 84
(79.3)
10 (71.4) 30 (71.4) 18 (81.8) 193
(75.7)
abAntipsychotic/antidepressant
medication
42 (60.9) 83
(78.3)
10 (71.4) 32 (76.2) 20 (90.9) 189
(74.1)
abDiagnosis of type 2 diabetes 42 (60.9) 75
(70.8)
10 (71.4) 34 (81.0) 20 (90.9) 183
(71.8)
Other psychiatric medication 32 (46.4) 70
(66.0)
10 (71.4) 24 (57.1) 12 (54.6) 150
(58.8)
abEthnicity 22 (31.9) 64
(60.4)
8 (57.1) 26 (61.9) 17 (77.3) 139
(54.5)
Red meat consumption 36 (52.2) 49
(46.2)
7 (50.0) 23 (54.8) 11 (50.0) 128
(50.2)
Caffeine consumption 34 (49.3) 51
(48.1)
8 (57.1) 23 (54.8) 5 (22.7) 122
(47.8)
cPoor sleep 33 (47.8) 44
(41.5)
5 (35.7) 19 (45.2) 12 (54.6) 114
(44.7)
Dehydration 25 (36.2) 34
(32.1)
6 (42.9) 17 (40.5) 3 (13.6) 86
(33.7)
Lack of access to green spaces 19 (27.5) 30
(28.3)
2 (14.3) 12 (28.6) 7 (31.8) 71
(27.8)
cAir pollution 19 (27.5) 22
(22.6)
3 (21.4) 13 (31.0) 3 (13.6) 63
(24.7)
Noise pollution 5 (7.3) 10 (9.4) 1 (7.1) 6 (14.3) 1 (4.6) 23 (9.0)
Vaccinations 5 (7.3) 4 (3.8) 0 1 (2.4) 1 (4.6) 11 (4.3)
Hair dye 3 (4.4) 3 (2.8) 0 0 0 6 (2.4)
Mobile phone use 2 (2.9) 3 (2.8) 0 1 (2.4) 0 6 (2.4)
aEstablished risk factors according to NICE; bEstablished risk factors according to CVD risk prediction scores applicable to people with schizophrenia [33, 34]; cNot
an established CVD risk factor according to NICE, but there is some evidence for it increasing CVD risk in published literature
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nurses (hospital) (93%), consultant psychiatrists (93%),
community psychiatric nurses (92%) and GP nurses
(91%) (Fig. 1). There was no significant difference be-
tween groups regarding perceptions of who had respon-
sibility for physical healthcare.
Interventions
In total 67% of participants said at some point they had
delivered an effective intervention to improve sedentary
behaviour in people with schizophrenia and groups dif-
fered significantly (χ2 = 28.67; p < 0.001). The group with
the highest proportion of participants to answer yes to
this question was nurses (83.5%, n = 86, 34% of the
total). The most common intervention across all groups
was signposting, i.e. directing patients to services or
sources of advice (38%, n = 64, 25% of the total) (Fig. 2).
In regards to government recommended interventions,
28% (n = 70) of participants had heard of MECC, of
whom 42% (n = 26, 10% of the total) stated they had
used this intervention with someone with schizophrenia.
38% (n = 97) of participants had heard of Very Brief Ad-
vice (VBA) on smoking, of whom 60% (n = 56, 22% of
the total) stated they had delivered this intervention to
someone with schizophrenia. 13% of participants (n =
Table 3 Comparison between groups on beliefs of risk factors for CVD
Ethnicity Diabetes Antipsychotic/antidepressant medication
N % N % N %
Non-qualified clinical staff 22 31.9 42 60.9 42 60.9
Nurses 64 60.4 75 70.8 83 78.3
Senior/managerial clinical staff 8 57.1 10 71.4 10 71.4
Allied health professionals 26 61.9 34 81.0 32 76.2
Medical practitioners 17 77.3 20 90.9 20 90.9
χ2 21.239 a9.772 a10.601
P < 0.001 0.04 0.03
aFisher’s exact was used due to some cell counts being < 5
Fig. 1 Whose responsibility is it to monitor the physical health of people with schizophrenia?
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33) believed they had heard of a non-existent interven-
tion, VBA on sedentary behaviour, of whom 68% (n = 21,
8% of the total sample) stated they had delivered this
intervention to someone with schizophrenia. There was
no significant difference between groups in whether they
had heard of MECC, VBA on smoking or the non-
existent intervention VBA on sedentary behaviour. Nor
did groups differ in whether they had delivered these in-
terventions to someone with schizophrenia.
Discussion
Knowledge of many established risk factors for CVD was
high, including some risk factors of particular relevance
to schizophrenia patients, such as smoking, obesity and
lack of physical activity. Other established risk factors of
age, diabetes and ethnicity were less widely known.
There was an educational gradient in recognition of dia-
betes, ethnicity and antipsychotic/antidepressant medi-
cation as risk factors, with more highly qualified
professionals more likely to correctly identify these risk
factors. Almost 75% of participants identified anti-
psychotic/antidepressant medication as a risk factor for
CVD. Of concern was that nearly 10% of medical practi-
tioners and over 20% of nurses were unaware that anti-
psychotic/antidepressant medication are risk factors for
CVD. Antipsychotic use is stated to increase CVD risk
in NICE guidance [32]. Antidepressant use was found to
be associated with increased risk of CVD, independent
of traditional risk factors in a CVD risk prediction model
for people with severe mental illness (SMI) [34]. As well
as cardiovascular side effects, antipsychotic treatment is
associated with metabolic syndrome [11]. These side ef-
fects can lead to non-adherence [37], which is associated
with increased use of healthcare resources [38] and re-
duced quality of life [39]. However, clinicians may experi-
ence reluctance to make changes to medication regimens,
despite health-related risks, as pharmacological treatment
for schizophrenia is often effective at treating psychotic
symptoms [40], as well as reducing adverse outcomes such
as relapse and hospitalisation [41].
A high proportion of participants across all profes-
sional groups selected substance abuse as a risk factor
for CVD (overall 81% of the whole sample). Studies from
the general population have shown recreational drugs
such as methamphetamine and cocaine can provoke a
multifactorial dysfunction of the cardiovascular system
[42, 43]. Prevalence of substance abuse is high in people
with schizophrenia [44], whereby between 40 and 50% of
people with schizophrenia may have a comorbid sub-
stance use disorder (SUD) [45]. This rate is about three
times as high as that of the general population [46].
SUDs are associated with poor treatment adherence and
response, increase symptoms and the risk of relapse
[46], and are associated with poorer physical health out-
comes [47]. Substance abuse is not cited as a CVD risk
factor in NICE guidance on CVD risk assessment and
prevention [31, 32], although NICE does recommend
monitoring the physical health of adults and young
people with psychosis and comorbid substance misuse
[48]. It was therefore reasonable for participants to iden-
tify substance use as a risk factor for CVD. A 2019 Lan-
cet Psychiatry Commission has highlighted that people
Fig. 2 Interventions for improving sedentary behaviour in people with schizophrenia
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with SMI and SUD are at an increased risk of physical
multimorbidity and addressing substance misuse within
mental health services should be a high priority [49].
However, access to secondary health care for people with
mental illness may be limited due to issues such as stigma
and fragmentation of care [49]. Subsequently, people with
mental illness and comorbid physical health problems
likely receive an inferior standard of health care compared
with the general population with the same physical health
problems [49]. There is therefore a need for investment in
integration of physical and mental health care.
Sleep problems have been linked to CVD in the general
population [29, 50, 51]. However, they have not been in-
cluded as such in NICE guidelines. Sleep problems are
highly prevalent in people with schizophrenia [16, 52] but
the link between sleep problems and CVD in schizophre-
nia requires more research. It is therefore not surprising
that less than half of participants endorsed sleep as a CVD
risk factor. If further research establishes sleep problems
as a risk factor for CVD in schizophrenia, the assessment
of sleep outcomes such as sleep quality and sleep duration
should become part of routine training for NHS staff that
support people with schizophrenia.
When examining whose responsibility participants felt
it was to monitor the physical health of people with
schizophrenia, there were high levels (over 90%) seen on
half the given options and there was no difference in re-
sponses between groups. This raises a risk of “diffusion
of responsibility”, in that the presence of other health-
care professionals providing support may make some
feel less personally responsible for monitoring physical
health [53]. Healthcare professionals in secondary care
may believe the responsibility lies with healthcare profes-
sionals in primary care and vice visa.
Comparisons between groups showed significant dif-
ferences in which healthcare professionals have delivered
interventions to improve sedentary behaviour in people
with schizophrenia, with nurses being the group with
the highest proportion. This suggests that some physical
health interventions are being incorporated into health-
care professionals’ patient consultations but perhaps in
an informal format. There was poor awareness of either
of the government recommended interventions, MECC
and VBA on smoking. While both MECC and VBA on
smoking are designed to be used during any patient
interaction, it appears they are not being implemented.
Further, this survey may have over-estimated awareness
of MECC and VBA on smoking as participants may have
responded ‘yes’ to all nominated interventions without
actually having heard of them, as suggested by the find-
ing that 33 participants were aware of the non-existent
VBA on sedentary behaviour.
Some limitations should be considered in the inter-
pretation of the findings of this study. Participants were
asked whether they had ever delivered any effective in-
terventions to improve sedentary behaviour in people
with schizophrenia and signposting and referrals were
provided as examples. First, the term ‘effective’ was not
defined and it is therefore possible participants might have
delivered an intervention, with no way of knowing
whether it was effective. Second, it was not surprising that
signposting and referrals were the two most common in-
terventions cited given these were examples provided.
This could therefore have been construed as suggestive.
Nonetheless, participants did cite other interventions in-
dependently such as encouragement and verbal advice.
A strength of this study was the large number of par-
ticipants across a range of clinical staff. The anonymity
of the survey also enabled participants to be honest in
their responses.
Conclusions
Healthcare professionals’ awareness of many established
risk factors for CVD is high but, only moderate numbers
identified sleep problems or antipsychotic/antidepressant
use as risk factors, with higher numbers identifying sub-
stance abuse despite this not appearing as a CVD risk
factor in NICE guidance [31, 32]. Previous research
found that the physical health of people with schizophre-
nia and related psychotic illnesses was not well moni-
tored or investigated [54]. While we did not ask
specifically about whether participants monitored pa-
tients’ physical health and risk factors for CVD, the lack
of awareness about some risk factors could mean that
monitoring of physical health is sub-optimal. Coupled
with the lack of clarity about responsibility for physical
health care, this raises the possibility that some risk fac-
tors may not be monitored and that an overall picture of
a patient’s CVD risk may not be considered. Poor phys-
ical health in people with SMI decreases well-being [39],
reduces adherence to prescribed medication [37] and
hinders recovery from mental health symptoms [38].
This adds to the social and economic burden of their
mental illness [55, 56]. We support the findings from the
2019 Lancet Psychiatry Commission that integrated care
models are needed, with clear lines of accountability and
responsibility, and good communication between pri-
mary and secondary care services [49].
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